FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037112506> ?p ?o ?g. }

• W2037112506 endingPage "S231" @default.
• W2037112506 startingPage "S230" @default.
• W2037112506 abstract "Taxol has produced the best response rate (21%) to date of all single agents in ECOG trials in NSCLC, with is activity confirmed at M.D. Anderson. In 1/94, we initiated a phase II trial of taxol single agent in patients with stage IIIb/IV NSCLC and no prior radio- and/or chemotherapy. In this trial, paclitaxel was administered over 3 h at a dose of 200 mg/m2 after premedication with dexamthasone, cimetidine and clemastine. The second and all further cycles were administered in an outpatient setting. Cycles were repeated at 28-day intervals. In this ongoing study, 25 patients—21 men and 4 women—with a median age of 60.4 (range, 42 to 69) have been treated to date. Patient characteristics included ECOG performance status 0–1, stage IIIb 7 and stage IV 18; and a histological diagnosis of squamous cell carcinoma in 15 patients (60%), adenocarcinoma 8 patients (32%), and 2 patients (8%) with poorly differentiated carcinoma. At this time, partial remissions have been noted in 7 patients (28%), no change occurred in 9 patients (36%) and 9 patients (36%) had progressive disease. Hematologic toxicities were mild; only one grade 3/4 (WHO) neutropenia was observed. Grade 3/4 myalgia was observed in 3 patients, and grade 4 constipation in one patient, further appeared in 9 men impotence. Conclusion, these results indicate that paclitaxel is an active new agent for the treatment of advanced NSCLC. Mild hematologic and nonhematologic toxicity's were observed with the 3-h Infusion. The firstly described appearance of impotence needs to be clarified in further investigations. The therapy was generally well tolerated. Taxol has produced the best response rate (21%) to date of all single agents in ECOG trials in NSCLC, with is activity confirmed at M.D. Anderson. In 1/94, we initiated a phase II trial of taxol single agent in patients with stage IIIb/IV NSCLC and no prior radio- and/or chemotherapy. In this trial, paclitaxel was administered over 3 h at a dose of 200 mg/m2 after premedication with dexamthasone, cimetidine and clemastine. The second and all further cycles were administered in an outpatient setting. Cycles were repeated at 28-day intervals. In this ongoing study, 25 patients—21 men and 4 women—with a median age of 60.4 (range, 42 to 69) have been treated to date. Patient characteristics included ECOG performance status 0–1, stage IIIb 7 and stage IV 18; and a histological diagnosis of squamous cell carcinoma in 15 patients (60%), adenocarcinoma 8 patients (32%), and 2 patients (8%) with poorly differentiated carcinoma. At this time, partial remissions have been noted in 7 patients (28%), no change occurred in 9 patients (36%) and 9 patients (36%) had progressive disease. Hematologic toxicities were mild; only one grade 3/4 (WHO) neutropenia was observed. Grade 3/4 myalgia was observed in 3 patients, and grade 4 constipation in one patient, further appeared in 9 men impotence. Conclusion, these results indicate that paclitaxel is an active new agent for the treatment of advanced NSCLC. Mild hematologic and nonhematologic toxicity's were observed with the 3-h Infusion. The firstly described appearance of impotence needs to be clarified in further investigations. The therapy was generally well tolerated." @default.
• W2037112506 created "2016-06-24" @default.
• W2037112506 creator A5030777479 @default.
• W2037112506 creator A5073566056 @default.
• W2037112506 creator A5080990526 @default.
• W2037112506 creator A5089783372 @default.
• W2037112506 date "1995-11-01" @default.
• W2037112506 modified "2023-10-05" @default.
• W2037112506 title "1107 Paclitaxel single agent in the first-line treatment of advanced NSCLC" @default.
• W2037112506 doi "https://doi.org/10.1016/0959-8049(95)96353-f" @default.
• W2037112506 hasPublicationYear "1995" @default.
• W2037112506 type Work @default.
• W2037112506 sameAs 2037112506 @default.
• W2037112506 citedByCount "1" @default.
• W2037112506 crossrefType "journal-article" @default.
• W2037112506 hasAuthorship W2037112506A5030777479 @default.
• W2037112506 hasAuthorship W2037112506A5073566056 @default.
• W2037112506 hasAuthorship W2037112506A5080990526 @default.
• W2037112506 hasAuthorship W2037112506A5089783372 @default.
• W2037112506 hasConcept C126322002 @default.
• W2037112506 hasConcept C141071460 @default.
• W2037112506 hasConcept C142724271 @default.
• W2037112506 hasConcept C143998085 @default.
• W2037112506 hasConcept C146357865 @default.
• W2037112506 hasConcept C151730666 @default.
• W2037112506 hasConcept C204787440 @default.
• W2037112506 hasConcept C27081682 @default.
• W2037112506 hasConcept C2776694085 @default.
• W2037112506 hasConcept C2776907518 @default.
• W2037112506 hasConcept C2777063308 @default.
• W2037112506 hasConcept C2777292972 @default.
• W2037112506 hasConcept C2777546739 @default.
• W2037112506 hasConcept C2778300832 @default.
• W2037112506 hasConcept C71924100 @default.
• W2037112506 hasConcept C86803240 @default.
• W2037112506 hasConcept C90924648 @default.
• W2037112506 hasConceptScore W2037112506C126322002 @default.
• W2037112506 hasConceptScore W2037112506C141071460 @default.
• W2037112506 hasConceptScore W2037112506C142724271 @default.
• W2037112506 hasConceptScore W2037112506C143998085 @default.
• W2037112506 hasConceptScore W2037112506C146357865 @default.
• W2037112506 hasConceptScore W2037112506C151730666 @default.
• W2037112506 hasConceptScore W2037112506C204787440 @default.
• W2037112506 hasConceptScore W2037112506C27081682 @default.
• W2037112506 hasConceptScore W2037112506C2776694085 @default.
• W2037112506 hasConceptScore W2037112506C2776907518 @default.
• W2037112506 hasConceptScore W2037112506C2777063308 @default.
• W2037112506 hasConceptScore W2037112506C2777292972 @default.
• W2037112506 hasConceptScore W2037112506C2777546739 @default.
• W2037112506 hasConceptScore W2037112506C2778300832 @default.
• W2037112506 hasConceptScore W2037112506C71924100 @default.
• W2037112506 hasConceptScore W2037112506C86803240 @default.
• W2037112506 hasConceptScore W2037112506C90924648 @default.
• W2037112506 hasLocation W20371125061 @default.
• W2037112506 hasOpenAccess W2037112506 @default.
• W2037112506 hasPrimaryLocation W20371125061 @default.
• W2037112506 hasRelatedWork W2129397417 @default.
• W2037112506 hasRelatedWork W2316397280 @default.
• W2037112506 hasRelatedWork W2339436080 @default.
• W2037112506 hasRelatedWork W2360084237 @default.
• W2037112506 hasRelatedWork W2415550183 @default.
• W2037112506 hasRelatedWork W2471790567 @default.
• W2037112506 hasRelatedWork W2755257004 @default.
• W2037112506 hasRelatedWork W2899360650 @default.
• W2037112506 hasRelatedWork W3147219444 @default.
• W2037112506 hasRelatedWork W3149674127 @default.
• W2037112506 hasVolume "31" @default.
• W2037112506 isParatext "false" @default.
• W2037112506 isRetracted "false" @default.
• W2037112506 magId "2037112506" @default.
• W2037112506 workType "article" @default.